Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack drug trial halted: could quick cholesterol drop save hearts?

NCT ID NCT05613426

Disease control Sponsor: Henan Institute of Cardiovascular Epidemiology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving a powerful cholesterol-lowering drug (evolocumab) very early after a major heart attack could help the heart pump better and prevent long-term damage. About 119 adults who were having a heart attack and scheduled for a procedure to open blocked arteries took part. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

119 people

The number who actually took part.

Started

Apr 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years * Persistent chest pain or chest discomfort * Onset within 12 hours * ST-segment elevation ≥0.1 millivolt in two adjacent precordial leads, or a new-onset left bundle branch block with dynamic changes * Primary PCI is planned Exclusion Criteria: * Contraindications to Statins or PCSK9 inhibitors * Prior intravenous thrombolytic therapy * Prior use of Statins, PCSK9 inhibitors or Ezetimibe * Cardiogenic shock * Acute heart failure or pulmonary edema * Prior chronic heart failure * Severe hepatic and renal insufficiency (alanine aminotransferase ≥5 upper limit of normal; estimated glomerular filtration rate \<30ml/min/1.73m2, or on dialysis) * Prolonged (\> 20 minutes) cardiopulmonary resuscitation * Definite mechanical complications (including ventricular septal perforation, or rupture of the Papillary tendon bundle, or rupture of the left ventricular free wall) * Malignant arrhythmias that are difficult to control with drugs * Severe chronic obstructive pulmonary disease or respiratory failure * Severe infection * Neurological disorders * Bleeding history of cerebrovascular, gastrointestinal, respiratory, urinary or other organs within the last month * Active bleeding or bleeding diatheses * Use of anticoagulants * Malignant tumors or other pathophysiological conditions with an expected survival time of less than 1 year * Pregnant or lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST elevation myocardial infarction (stemi) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST elevation myocardial infarction (stemi)

Contacts and locations

Locations

  • Fuwai Central China Cardiovascular Hospital

    Zhengzhou, Henan, China

  • Hopeshine Minsheng Hospital of Xinzheng

    Xinzheng, Henan, China

  • Kaifeng Central Hospital

    Kaifeng, Henan, China

  • The People's Hospital of Changyuan

    Xinxiang, Henan, China

  • The People's Hospital of Gongyi

    Gongyi, Henan, China

  • The People's Hospital of Xuchang

    Xuchang, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.